Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous Glassia treatment in lung transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Rejection in Transplantation
• Lung Transplantation-related Rejection

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Kamada, Ltd. | Conditions: Transplantation, Lung Rejection | Phase 2 | Status: COMPLETED